ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Completed · Phase 2

Conditions studied: Parkinson Disease

In brief

After a screening evaluation including baseline clinical laboratory testing, a physical and neurological evaluation, subjects will be asked to undergo an injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging. Subjects will undergo a second injection of ALTROPANE® followed by up to 60 minutes of serial dynamic imaging within 2-6 weeks of the injection 1.

Key facts

Study ID

NCT00397228

Run by

Molecular NeuroImaging

People needed

27

Starts

2006-11-01

Expected to finish

2011-12-01

Last updated by the study team

2016-12-16

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The participant is 30 years or older at time of PD diagnosis.
• Written informed consent is obtained.
• Participants have a clinical diagnosis of idiopathic Parkinson's disease of < 7 years.
• Hoehn and Yahr stages I-III.
• Negative drug screen

You may not qualify if…

• The participant has atypical or drug-induced Parkinson's disease.
• The participant has dementia.
• The participant has a clinically significant clinical laboratory value and/or clinically significant unstable medical or psychiatric illness.
• Treatment within the six months prior to screening with bupropion, methylphenidate, reserpine, alpha methyldopa, or amphetamine.
• The participant has a history of alcohol, narcotic, or any other drug abuse within the past 2 years.
• The participant has received an investigational drug within 60 days of screening visit.
• Pregnancy

Where it is running

• Molecular NeuroImaging — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.